Objective: miRNA-based therapies have a several problems including tissue specificity deficiency, lack of an optimal delivery system, poor cell uptake, and systemic toxicity risk. The aim of this study is to develop a cationic lipid-based miRNA delivery system that can address some of these problems and be used to treat diabetes. Methods: We created coated, cationic lipoparticles (CCLs) containing miRNA in the core and decorating with various peptides to target beta-cells. And the concentration rates of CCLs were observed to study liposome delivery efficiency. To study the liposome effect for delivering miRNA, we assessed cellular uptake in various cell lines with fluorescence microscopy. Results: Intracellular delivery efficiency was the highest in the liposome made from Ex-4 (9-30) peptides among various liposomes and Ex-4 (9-30) 3x showed the highest efficiency in concentration test results. The cellular uptakes showed that Ex-4 (9-30) liposome was found to be delivered in beta cell line, but not found in other cell lines. Conclusion: We have shown that nanoparticle EX4-CCL-miRNAs specifically transfer miRNAs to pancreatic beta-cells. These results suggest that EX4-CCL-miRNA plays an important role as a miRNA carrier for the treatment of diabetes.